Skip to main content
Erschienen in: Der Urologe 8/2004

01.08.2004 | Leitthema

Bedeutung von Komorbidität und Alter bei der radikalen Prostatektomie

verfasst von: Prof. Dr. M. Wirth, M. Fröhner

Erschienen in: Die Urologie | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Zusammenfassung

Komorbidität ist das gleichzeitige Vorliegen einer oder mehrerer weiterer Diagnosen neben der behandelten Erkrankung. Die mittlere Zahl der Begleiterkrankungen nimmt mit dem Alter zu. Bei Kandidaten für eine radikale Prostatektomie sind 2 Aspekte der Komorbidität von Interesse: ihre Assoziation mit perioperativen Komplikationen und mit dem langfristigen Überleben. Zur Vorhersage der Langzeitprognose ist der Charlson-Score die am umfangreichsten untersuchte Komorbiditätsklassifikation. Dieser Score wurde beim Prostatakarzinom als unabhängiger Prognosefaktor identifiziert. Auch Daten der präoperativen kardiopulmonalen Risikoabschätzung können zur Identifikation von Patienten mit einem erhöhten Mortalitätsrisiko genutzt werden. Die Aussagekraft der Komorbidität erscheint hinsichtlich der Vorhersage der Gesamtmortalität in etwa der des Gleason-Scores, dem wichtigsten überlebensrelevanten tumorassoziierten Faktor, vergleichbar. Die Identifikation prognoserelevanter Einzelerkrankungen und die Entwicklung einer „für die radikale Prostatektomie spezifischen“ Komorbiditätsklassifikation könnte in Zukunft die Stratifizierung der Patienten verbessern, die für diesen Eingriff in Frage kommen.
Literatur
1.
Zurück zum Zitat Yates JW (2001) Comorbidity considerations in geriatric oncology research. CA Cancer J Clin 51:329–336PubMed Yates JW (2001) Comorbidity considerations in geriatric oncology research. CA Cancer J Clin 51:329–336PubMed
2.
Zurück zum Zitat Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base. J Clin Oncol 19:1147–1151PubMed Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base. J Clin Oncol 19:1147–1151PubMed
3.
Zurück zum Zitat Froehner M (2003) Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 170:1954 Froehner M (2003) Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 170:1954
4.
Zurück zum Zitat de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56:221–229CrossRefPubMed de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56:221–229CrossRefPubMed
5.
Zurück zum Zitat Coebergh JWW, Janssen-Heijnen MLG, Post PN, Razenberg PPA (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the Southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52:1131–1136CrossRefPubMed Coebergh JWW, Janssen-Heijnen MLG, Post PN, Razenberg PPA (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the Southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52:1131–1136CrossRefPubMed
6.
Zurück zum Zitat Wirth MP, Froehner M (2000) Comorbidity in prostate cancer. Aging Male 3:132–136 Wirth MP, Froehner M (2000) Comorbidity in prostate cancer. Aging Male 3:132–136
7.
Zurück zum Zitat Repetto L, Fratino L, Audisio RA et al. (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494–502CrossRefPubMed Repetto L, Fratino L, Audisio RA et al. (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494–502CrossRefPubMed
8.
Zurück zum Zitat Jani AB, Hellmann S (2003) Early prostate cancer: clinical decision making. Lancet 361:1045–1053CrossRefPubMed Jani AB, Hellmann S (2003) Early prostate cancer: clinical decision making. Lancet 361:1045–1053CrossRefPubMed
9.
Zurück zum Zitat Catalona WJ, Ramos GR, Carvalhal GF (1999) Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49:282–286PubMed Catalona WJ, Ramos GR, Carvalhal GF (1999) Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49:282–286PubMed
10.
Zurück zum Zitat Wirth M, Fröhner M (2000) Diagnostik und individualisierte Therapie des lokoregionären Prostatakarzinoms. Urologe [A] 39:578–587 Wirth M, Fröhner M (2000) Diagnostik und individualisierte Therapie des lokoregionären Prostatakarzinoms. Urologe [A] 39:578–587
11.
Zurück zum Zitat Froehner M, Litz R, Manseck A, Hakenberg OW, Leike S, Albrecht DM, Wirth MP (2001) Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy. Urol Int 67:283–288CrossRefPubMed Froehner M, Litz R, Manseck A, Hakenberg OW, Leike S, Albrecht DM, Wirth MP (2001) Relationship of comorbidity, age and perioperative complications in patients undergoing radical prostatectomy. Urol Int 67:283–288CrossRefPubMed
12.
Zurück zum Zitat Dillioglugil Ö, Leibman BD, Leibman, NS, Kattan MW, Rosas AL, Scardino PT (1997) Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 157:1760–1767CrossRefPubMed Dillioglugil Ö, Leibman BD, Leibman, NS, Kattan MW, Rosas AL, Scardino PT (1997) Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 157:1760–1767CrossRefPubMed
13.
Zurück zum Zitat Rosenblum N, Lepor H (2001) Radical retropubic prostatectomy. Preoperative management. Urol Clin North Am 28:499–507PubMed Rosenblum N, Lepor H (2001) Radical retropubic prostatectomy. Preoperative management. Urol Clin North Am 28:499–507PubMed
14.
15.
Zurück zum Zitat Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132CrossRefPubMed Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132CrossRefPubMed
16.
Zurück zum Zitat Barry MJ, Albertsen PC, Bagshaw MA et al. (2001) Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 91:2302–2314CrossRefPubMed Barry MJ, Albertsen PC, Bagshaw MA et al. (2001) Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 91:2302–2314CrossRefPubMed
17.
Zurück zum Zitat Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP (2003) Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 62:698–701CrossRefPubMed Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP (2003) Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 62:698–701CrossRefPubMed
18.
Zurück zum Zitat Fowler JE, Terrell FL, Renfroe DL (1996) Co-Morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 156:1714–1718CrossRefPubMed Fowler JE, Terrell FL, Renfroe DL (1996) Co-Morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 156:1714–1718CrossRefPubMed
19.
Zurück zum Zitat Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980CrossRefPubMed Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980CrossRefPubMed
20.
Zurück zum Zitat Piccirillo JK (2000) Importance of comorbidity in head and neck cancer. Laryngoscope 110:593–602CrossRefPubMed Piccirillo JK (2000) Importance of comorbidity in head and neck cancer. Laryngoscope 110:593–602CrossRefPubMed
21.
Zurück zum Zitat Post PN, Hansen BE, Kil PJM, Janssen-Heijnen MLG, Coebergh JWW (2001) The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU International 87:821–826CrossRefPubMed Post PN, Hansen BE, Kil PJM, Janssen-Heijnen MLG, Coebergh JWW (2001) The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU International 87:821–826CrossRefPubMed
22.
Zurück zum Zitat Fowler JE, Bigler SA, White PC, Duncan WL (2002) Hormone therapy for locally advanced prostate cancer. J Urol 168:546–549CrossRefPubMed Fowler JE, Bigler SA, White PC, Duncan WL (2002) Hormone therapy for locally advanced prostate cancer. J Urol 168:546–549CrossRefPubMed
23.
Zurück zum Zitat Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H (2002) Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168:525–529CrossRefPubMed Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H (2002) Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168:525–529CrossRefPubMed
24.
Zurück zum Zitat Froehner M, Koch R, Litz R, Haase M, Oehlschlaeger S, Wirth MP (2004) Comparison of the prognostic significance of tumor-related and comorbidity-related predictors of overall mortality after radical prostatectomy. J Urol (Abstract, in press) Froehner M, Koch R, Litz R, Haase M, Oehlschlaeger S, Wirth MP (2004) Comparison of the prognostic significance of tumor-related and comorbidity-related predictors of overall mortality after radical prostatectomy. J Urol (Abstract, in press)
25.
Zurück zum Zitat Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200CrossRefPubMed Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200CrossRefPubMed
26.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMed
27.
Zurück zum Zitat Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980CrossRefPubMed Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980CrossRefPubMed
28.
Zurück zum Zitat Froehner M, Koch R, Litz R et al. (2003) Preoperative cardiopulmonary risk assessment as predictor of early non-cancer and overall mortality after radical prostatectomy. Urology 61:596–600CrossRefPubMed Froehner M, Koch R, Litz R et al. (2003) Preoperative cardiopulmonary risk assessment as predictor of early non-cancer and overall mortality after radical prostatectomy. Urology 61:596–600CrossRefPubMed
29.
Zurück zum Zitat Reid BC, Alberg AJ, Klassen AC, Koch WM, Samet JM (2001) The American Society of Anesthesiologists‘ class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck 23:985–994CrossRefPubMed Reid BC, Alberg AJ, Klassen AC, Koch WM, Samet JM (2001) The American Society of Anesthesiologists‘ class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck 23:985–994CrossRefPubMed
30.
Zurück zum Zitat Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP (2004) Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 171:697–699PubMed Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP (2004) Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 171:697–699PubMed
Metadaten
Titel
Bedeutung von Komorbidität und Alter bei der radikalen Prostatektomie
verfasst von
Prof. Dr. M. Wirth
M. Fröhner
Publikationsdatum
01.08.2004
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 8/2004
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-004-0640-4

Weitere Artikel der Ausgabe 8/2004

Der Urologe 8/2004 Zur Ausgabe

Berufspolitik Österr.Berufsverband

Berufspolitik Österreichischer Berufsverband

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.